Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071060 | 0.86 | SMN1; SMN2 (0.53) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL21020932 | 0.85 | TSHR (0.48) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL22295672 | 0.79 | HSD17B3 (0.53) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL24777326 | 0.76 | MEN1 (0.36) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL14215981 | 0.76 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL12959710 | 0.75 | MEN1 (0.46) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL17461304 | 0.74 | MAOA (0.54) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL1870741 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL19334272 | 0.73 | MAOA (0.53) | MEN1KMT2AUSP2SIGMAR1TSHR | |
| SCHEMBL142090 | 0.71 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AUSP2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1446815-A | Benzoindoline spironaphthoxazine compound and synthesis method and application thereof | RES INST OF PHYSICS AND CHEMIS (CN) | 2003-10-08 | — | — | CN | claimed |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | RAIN THERAPEUTICS INC. | 2021-11-11 | — | — | US | disclosed |
| WO-2021218755-A1 | SHP2 INHIBITOR, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2020-08-27 | — | — | US | disclosed |
| WO-2020160174-A1 | USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2020-08-06 | — | — | WO | disclosed |
| CN-104870446-B | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-108047219-A | Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, its preparation method and its purposes as kinase inhibitor | 内尔维阿诺医学科学有限公司 | 2018-05-18 | — | — | CN | disclosed |
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | disclosed |
| WO-2016034134-A1 | HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-10 | — | — | WO | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1771169-A1 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1298783-C | Preparation of polyvinyl butyral from photochromic nano composite material and its method | YANHUA NEW MATERIAL CO LTD TIA (CN) | 2007-02-07 | — | — | CN | disclosed |
| CN-1283745-C | Nano composite materials and products of photochromism of heterocyclic ring substituted spirooxazine compounds | UNIV NANKAI (CN) | 2006-11-08 | — | — | CN | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006019831-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| CN-1687300-A | Nano composite materials and products of photochromism of heterocyclic ring substituted spirooxazine compounds | UNIV NANKAI (CN) | 2005-10-26 | — | — | CN | disclosed |
| CN-1640929-A | Preparation of polyvinyl butyral from photochromic nano composite material and its method | YANHUA NEW MATERIAL CO LTD TIA (CN) | 2005-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | EGFR, BRCA1, ERBB2 | ALDH1A1 895/4885MEN1 347/4885KMT2A 292/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885MEN1 4800/4885KMT2A 4464/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | ALDH1A1 591/4885MEN1 4815/4885KMT2A 3974/4885 |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | EGFR, VHL, MYC | ALDH1A1 1217/4885MEN1 42/4885KMT2A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.